ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$5.01
-0.06 (-1.18%)
Open$5.04
Previous Close$5.07
Day High$5.06
Day Low$4.98
52W High$5.45
52W Low$3.50
Volume—
Avg Volume3.81M
Market Cap1.00B
P/E Ratio6.54
EPS$0.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+923.0% upside
Current
$5.01
$5.01
Target
$51.25
$51.25
$34.47
$51.25 avg
$59.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.68M | 20.61M | 146.67M |
| Net Income | -34,905,361 | -44,121,945 | -16,611,843 |
| Profit Margin | -237.9% | -226.0% | -11.3% |
| EBITDA | -39,398,328 | -52,567,993 | -23,689,130 |
| Free Cash Flow | — | — | -19,958,595 |
| Rev Growth | -28.8% | -28.8% | -8.1% |
| Debt/Equity | 0.04 | 0.04 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |